Insolvency case: NCLAT stays eviction of Sterling Biotech from its premises

Besides, the appellate tribunal also said that 'the Liquidator cannot sell the assets of the premises in question'

Sterling Biotech
Logo of Sterling Biotech
Press Trust of India New Delhi
3 min read Last Updated : Aug 05 2019 | 12:47 AM IST

The National Company Law Appellate Tribunal (NCLAT) has stayed eviction of Sterling Biotech from its premises as the debt-ridden company was going under the insolvency resolution process and was under the moratorium period.

A two-member bench headed by NCLAT Chairman Justice S J Mukhopadhaya upheld the order passed by the Mumbai Bench of the National Company Law Tribunal (NCLT), which had asked Srei Infrastructure Finance, a financial creditor, to hand over the possession of the A and B wing premises of Laxmi Towers.

The appellate tribunal observed that although Sterling Biotech, which is presently going through liquidation, is not the owner of the premises it cannot be ejected or disturbed during the moratorium period as the company has to remain as a going concern.

"We hold that the Adjudicating Authority (NCLT) has rightly directed the Appellant to hand over the possession of B' Wing premises of Lakshmi Towers and rightly prohibited the Appellant from evicting the Corporate Debtor (Sterling Biotech) from A' Wing premises of Lakshmi Towers," said NCLAT.

However, it also said that "So far as the question as to who is the owner of A' and B' Wings premises of Lakshmi Towers and whether the Appellant has any right over the said property, such questions are not required to be determined in the proceeding under the I&B Code'."

NCLAT also said if Sterling Biotech is saved during the liquidation proceeding or if it is sold to a third party along with the employees then, in such case, one may move before the Competent Court of law for appropriate decision.

Besides, the appellate tribunal also said that "the Liquidator cannot sell the assets of the premises in question."

Resolution Professional of Sterling Biotech had moved NCLT against the financial creditor to return the possession of B Wing premises of Lakshmi Towers and restrain Srei Infrastructure Finance from taking any action in relation to A Wing premises, which had allowed it.

Following which, Srei Infrastructure Finance moved NCLAT.

It had contended that the property in question does not belong to Sterling Biotech and being a third party property, the order of Moratorium' passed under Section 14 of the I&B Code' will not be applicable.

Opposing it, the RP had submitted that it amounts to obstruction in the matter of keeping Sterling Biotech as a going concern.

Sterling Biotech, whose promoters Nitin Jayantilal Sandesara and Chetankumar Jayantilal Sandesara are absconding, has a total debt of over Rs 9,000 crore.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Sterling Biotech case

First Published: Aug 04 2019 | 4:10 PM IST

Next Story